Key result
Brain natriuretic peptide (BNP) serves as a protective biomarker in heart-kidney interactions, potentially counteracting the renin-angiotensin-aldosterone system in heart failure and kidney disease.
Why the study?
Although BNP levels are known to be relatively higher in patients with chronic kidney disease without heart disease, the underlying mechanism remains unknown.
Answers are grounded in this paper and cite their sources.
This review highlights the protective role of BNP in heart-kidney interactions, suggesting that a better understanding of these mechanisms could accelerate pharmacological treatments for heart-kidney disease.
Brain natriuretic peptide (BNP) is an important biomarker for patients with heart failure, hypertension and cardiac hypertrophy. Although it is known that BNP levels are relatively higher in patients with chronic kidney disease and no heart disease, the mechanism remains unknown. Here, we review the functions and the roles of BNP in the heart-kidney interaction. In addition, we discuss the relevant molecular mechanisms that suggest BNP is protective against chronic kidney diseases and heart failure, especially in terms of the counterparts of the renin-angiotensin-aldosterone system (RAAS). The renal medulla has been reported to express depressor substances. The extract of the papillary tips from kidneys may induce the expression and secretion of BNP from cardiomyocytes. A better understanding of these processes will help accelerate pharmacological treatments for heart-kidney disease.
No takes yet. Share an insight, caveat, or question.
Okamoto et al. (2019) conducted a review in Heart failure and chronic kidney disease. Brain natriuretic peptide (BNP) was evaluated. Brain natriuretic peptide (BNP) serves as a protective biomarker in heart-kidney interactions, potentially counteracting the renin-angiotensin-aldosterone system in heart failure and kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: